Revenue: $447.7 million, an increase of 5.7% over the prior year. Net Income: $17.2 million. Diluted EPS: $0.23 per share. Cash Flow from Operations: $32.1 million, an increase of $41.3 million over the prior year. Environmental Services Revenue: $196.3 million with a margin of 10.8%. Dietary Services Revenue: $251.3 million with a margin of 7.6%.
Unity Biotechnology, Inc. SOUTH SAN FRANCISCO, Calif., April 22, 2025 (GLOBE NEWSWIRE) — UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today reported financial results for the first quarter ended March 31, 2025. UNITY announced 24-week and partial 36-week topline data from our Phase 2b
Mural Oncology, Inc. Following review of data from the phase 2 ARTISTRY-6 trial and previously announced results from the phase 3 ARTISTRY-7 trial, Mural will discontinue all clinical development of nemvaleukin With $144.4 million in cash as of December 31, 2024, Mural plans to explore strategic alternatives and will undertake a reduction in force of
Cash, Cash Equivalents, and Marketable Securities: Approximately $4 million as of December 31, 2024. Research and Development Expenses: $6.2 million for the year ended December 31, 2024, compared to $10.9 million for the year ended December 31, 2023. General and Administrative Expenses: $13.7 million for the year ended December 31, 2024, compared to $21.1 million
Q: How is the pace and quality of enrollment in Asia compared to the US? A: The pace of enrollment in Asia is about 2 to 4 times faster than in the US. The sites in Asia ramped up faster, and in the past few months, the output from Asia has matched that of the
Total Revenue: $25.4 million, up 2% from $25 million in 2023. Cloud Infrastructure and Disaster Recovery Service Revenue: $12.3 million, a 27% increase year-over-year. Annual Recurring Revenue Run Rate: $21.5 million. Net Income: $513,000, up 71% from $299,000 in 2023. Adjusted EBITDA: $2.37 million, compared to $1.64 million last year. Cash and Marketable Securities: $12.3
TORONTO, March 31, 2025–(BUSINESS WIRE)–Kontrol Technologies Corp. (CBOE.CA:KNR) (OTCQB:KNRLF) (FSE:1K8) (“Kontrol Technologies” or “Kontrol” or “Company”) announces its results for the three months and fiscal year ended December 31, 2024. A complete set of the Financial Statements and Management’s Discussion & Analysis have been filed on SEDAR (www.sedarplus.ca). Fourth Quarter and Fiscal Year 2024 Highlights
Cash and Marketable Securities: $231.5 million as of the end of 2024. R&D Expenses: $93.8 million in 2024, increased due to ALTITUDE-AD trial support. G&A Expenses: $20.2 million in 2024, roughly flat compared to the prior year. Loss from Operations: $114 million in 2024. Net Loss: $102.3 million in 2024, after accounting for interest income.
Research and Development Expenses (Q4 2024): $6 million, up from $4 million in Q4 2023. Research and Development Expenses (Full-Year 2024): $19.4 million, up from $16.5 million in 2023. Net Loss (Q4 2024): $12.1 million, compared to $6.7 million in Q4 2023. Net Loss (Full-Year 2024): $62.3 million, compared to $27.0 million in 2023. Stock
Cash Equivalents and Marketable Securities: $588 million at year-end 2024, up from $239 million at December 31, 2023. Loss from Operations: $241.4 million for the year ending December 31, 2024, compared to $179.7 million in 2023. Cost of Sales: $11.4 million following BLA approval for obe-cel. Research and Development Expenses: $138.4 million for the year